Literature DB >> 33448186

Regulation of DNA double-strand break repair pathway choice: a new focus on 53BP1.

Fan Zhang1, Zihua Gong2.   

Abstract

Maintenance of cellular homeostasis and genome integrity is a critical responsibility of DNA double-strand break (DSB) signaling. P53-binding protein 1 (53BP1) plays a critical role in coordinating the DSB repair pathway choice and promotes the non-homologous end-joining (NHEJ)-mediated DSB repair pathway that rejoins DSB ends. New insights have been gained into a basic molecular mechanism that is involved in 53BP1 recruitment to the DNA lesion and how 53BP1 then recruits the DNA break-responsive effectors that promote NHEJ-mediated DSB repair while inhibiting homologous recombination (HR) signaling. This review focuses on the up- and downstream pathways of 53BP1 and how 53BP1 promotes NHEJ-mediated DSB repair, which in turn promotes the sensitivity of poly(ADP-ribose) polymerase inhibitor (PARPi) in BRCA1-deficient cancers and consequently provides an avenue for improving cancer therapy strategies.

Entities:  

Keywords:  DNA double-strand break (DSB); Homologous recombination (HR); Non-homologous end-joining (NHEJ); P53-binding protein 1 (53BP1); Poly(ADP-ribose) polymerase inhibitor (PARPi)

Year:  2021        PMID: 33448186     DOI: 10.1631/jzus.B2000306

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  3 in total

1.  Pulsed low-dose rate radiotherapy has an improved therapeutic effect on abdominal and pelvic malignancies.

Authors:  Xin Wen; Hui Qiu; Zhiying Shao; Guihong Liu; Nianli Liu; Aoxing Chen; Xingying Zhang; Xin Ding; Longzhen Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2021 Sept 15       Impact factor: 3.066

Review 2.  Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors.

Authors:  Claudia Piombino; Laura Cortesi
Journal:  Cancers (Basel)       Date:  2022-06-05       Impact factor: 6.575

Review 3.  H2A.X Phosphorylation in Oxidative Stress and Risk Assessment in Plasma Medicine.

Authors:  Clarissa S Schütz; Matthias B Stope; Sander Bekeschus
Journal:  Oxid Med Cell Longev       Date:  2021-12-13       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.